Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001
- 1 May 2003
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (5) , 1689-1693
- https://doi.org/10.1128/aac.47.5.1689-1693.2003
Abstract
The activity of daptomycin was assessed by using 6,973 gram-positive bacteria isolated at 50 United States hospitals in 2000 and 2001. Among the isolates of Streptococcus pneumoniae ( n = 1,163) collected, the rate of penicillin resistance was 16.1%; rates of oxacillin resistance among Staphylococcus aureus isolates ( n = 1,018) and vancomycin resistance among Enterococcus faecium isolates ( n = 368) were 30.0 and 59.5%, respectively. Multidrug-resistant (MDR) phenotypes (isolates resistant to three or more different chemical classes of antimicrobial agents) accounted for 14.2% of S. pneumoniae isolates, 27.1% of S. aureus isolates, and 58.4% of E. faecium isolates. For all gram-positive species tested, MICs at which 90% of the isolates tested were inhibited (MIC 90 s) and MIC ranges for directed-spectrum agents (daptomycin, quinupristin-dalfopristin, and linezolid) were identical or highly similar for isolates susceptible or resistant to other agents or MDR. Daptomycin had a MIC 90 of 0.12 μg/ml for both penicillin-susceptible and -resistant isolates of S. pneumoniae . Against oxacillin-resistant S. aureus daptomycin had a MIC 90 of 0.5 μg/ml, and it had a MIC 90 of 4 μg/ml against both vancomycin-susceptible and -resistant E. faecium . The MIC 90 s for daptomycin and other directed-spectrum agents were unaffected by the regional or anatomical origin of isolates or patient demographic parameters (patient age, gender, and inpatient or outpatient care). Our results confirm the gram-positive spectrum of activity of daptomycin and that its activity is independent of susceptibility or resistance to commonly prescribed and tested antimicrobial agents. This study may serve as a baseline to monitor future changes in the susceptibility of gram-positive species to daptomycin following its introduction into clinical use.Keywords
This publication has 29 references indexed in Scilit:
- Resistance Studies with DaptomycinAntimicrobial Agents and Chemotherapy, 2001
- In Vitro Activities of Daptomycin against 2,789 Clinical Isolates from 11 North American Medical CentersAntimicrobial Agents and Chemotherapy, 2001
- Need for Annual Surveillance of Antimicrobial Resistance in Streptococcus pneumoniae in the United States: 2-Year Longitudinal AnalysisAntimicrobial Agents and Chemotherapy, 2001
- Bactericidal Activities of Two Daptomycin Regimens against Clinical Strains of Glycopeptide Intermediate-Resistant Staphylococcus aureus , Vancomycin-Resistant Enterococcus faecium , and Methicillin-Resistant Staphylococcus aureus Isolates in an In Vitro Pharmacodynamic Model with Simulated Endocardial VegetationsAntimicrobial Agents and Chemotherapy, 2001
- Nosocomial Bloodstream Infections: Organisms, Risk Factors, and ImplicationsClinical Infectious Diseases, 2000
- Emerging Therapies for Serious Gram-Positive Bacterial Infections: A Focus on LinezolidClinical Infectious Diseases, 2000
- Daptomycin: a novel agent for Gram-positive infectionsExpert Opinion on Investigational Drugs, 1999
- Effects of reduced cation supplement recommendations (National Committee for Clinical Laboratory Standards) on daptomycin antistaphylococcal activityAntimicrobial Agents and Chemotherapy, 1989
- Comparative in vitro activity of IY146032 (daptomycin), a new lipopeptide antimicrobialEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987
- In vitro activity of LY146032 (Daptomycin), a new peptolideEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987